Evidence map›Paper›PMID 33092785›Full record

ReviewAnnales de cardiologie et d'angeiologie2020

[COVID-19 and mechanical circulatory support].

G Hekimian, C Frere, J-P Collet

Open access · bronzeAbstract readReview
In one paragraph

Review in Annales de cardiologie et d'angeiologie, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

G HekimianMédecine intensive et réanimation, Sorbonne Université, groupe hospitalier Pitié-Salpêtrière (AP-HP), 75013 Paris, France. Electronic address: Guillaume.hekimian@aphp.fr.
C FrereHématologie biologique, Sorbonne Université, groupe hospitalier Pitié-Salpêtrière (AP-HP), 75013 Paris, France. Electronic address: Corinne.frere@aphp.fr.
J-P ColletACTION Study Group, Inserm UMR_S 1166, Institut de cardiologie, Paris Sorbonne Université (UPMC), Pitié-Salpêtrière Hospital (AP-HP), Paris, France. Electronic address: Jean-philippe.collet@aphp.fr.
Sorbonne Université · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracorporeal membrane oxygenation (ECMO) is mainly used as a rescue therapy in COVID-19 patients with severe acute respiratory distress syndrome (ARDS). More rarely, COVID-19 can be complicated by hemodynamic failure due to fulminant myocarditis or massive pulmonary embolism necessitating the implantation of venous-arterial ECMO. The management of ECMO during the COVID-19 pandemic is challenging due to some specificities related to the disease characteristics, such as the management of anticoagulation in patients with a hypercoagulable state and an increased risk of venous thromboembolism. In large retrospective cohorts, survival of ECMO-rescued COVID-19 patients with ADRS was reported to be similar to that reported in previous studies on ECMO support for severe ARDS. Full consideration of ECMO candidacy is crucial for appropriate allocation of resources.

Indexed as

Extracorporeal Membrane OxygenationCOVID-19HumansRespiratory Distress SyndromeAcute respiratory distress syndromeAnticoagulationCoagulopathieCOVID-19ECMOEmbolie pulmonaireExtracorporeal membrane oxygenationFulminant myocarditisMassive pulmonary embolismMyocardite fulminanteSDRA

Identifiers

PMID33092785
PMCPMC7543685
OpenAlexW3092617928

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.